Retatrutide Synedica 40 mg (Retatrutide 40 mg) in a pre-filled pen. Convenient dosing system, high quality and a modern format.
12,761 UAH
Orders are processed and handed over for delivery within 1–2 business days after confirmation by a manager. We deliver throughout Ukraine with Nova Poshta to a branch, parcel locker, or by courier to your address. Delivery cost is calculated at the carrier’s rates upon receipt.
Payment: Pay on delivery · Card transfer · Bank transfer · Crypto wallet · PayPal
Cagri Reta is a combination of Cagrilintide and Retatrutide that attracts the attention of people looking for information on appetite control, constant hunger, cravings for sweets and modern approaches to weight loss.
The Cagri Reta Dual Pen Kit Synedica contains Cagrilintide 4 mg and Retatrutide 40 mg in a ready-to-use pen format.
Cagrilintide is a long-acting amylin analogue that is being studied for its effects on satiety and food intake.
Retatrutide is an experimental triple agonist of the GLP-1, GIP and glucagon receptors that is being studied for the treatment of obesity and metabolic disorders.
That is why the queries “Cagri Reta”, “Cagrilintide + Retatrutide”, “retatrutide and cagrilintide”, “appetite control” and “what to do if weight is stagnant” are becoming increasingly popular.
Important: Retatrutide and Cagrilintide remain investigational molecules and are not approved drugs for the independent treatment of obesity. The information on the page is for informational purposes only.
You can also get a consultation with a doctor on the selection of peptides.
| Active ingredient | Retatrutide, Cagrilintide |
|---|---|
| Product form | Pre-filled pen |
| Dosage | 40mg+4mg |
| Route of administration | Subcutaneous injection |
| Requires reconstitution | No |
| Storage conditions | 2–8 °C (refrigerated) |
| Quantity per package | 2 pre-filled pens |
| Country of origin | Німеччина |
Cagri Reta is a combination of two investigational molecules: Cagrilintide and Retatrutide. The combination is being studied in the context of appetite control, satiety, body weight, and metabolic parameters.
Cagrilintide is a long-acting amylin analog and is being studied for its effects on satiety and food intake. Retatrutide acts as a triple agonist of GLP-1, GIP, and glucagon receptors and is being investigated for the treatment of obesity.
These molecules have different mechanisms of action, so their combination is being studied as a potential approach to affecting appetite, satiety, and weight loss. Such combinations should not be chosen independently.
Cagrilintide and Retatrutide are being studied separately for their effects on appetite, food intake, and body weight. The efficacy and safety of a specific combination product should not be equated with the results of clinical trials of the individual molecules.
These are molecules with different mechanisms of action, so it is not correct to directly compare them. The choice of approach depends on the goals, health status, and medical indications.
Tirzepatide is a GIP/GLP-1 receptor agonist, while Retatrutide is being investigated as a GLP-1/GIP/glucagon triple agonist, and Cagrilintide is an amylin analog. These are different molecules and different mechanisms of action.
Retatrutide and Cagrilintide remain investigational molecules as of 2026 and should not be presented as an approved combination treatment for weight loss alone.
The declared composition of the kit: Cagrilintide 4 mg + Retatrutide 40 mg in syringe pen format.